Edgewise Therapeutics, Inc.

Stage 3 · Topping · week 2

As of Oct 22, 2026, Edgewise Therapeutics is in Stage 3, the topping phase, now in week 2 (since Oct 15, 2026). It closed at $39.99, 17.3% below its 52-week high and above its 200-day average, which is rising.

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. More about the company

$39.99

+0.86% today

$4.3B · Mid cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is EWTX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 16w

S2 15w

S2 33w

S4 14w

S2 46w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 16w → S1 4w → S2 15w → S3 3w → S2 33w → S3 13w → S4 14w → S1 1w → S4 9w → S1 10w → S2 46w → S3 1w current

Total tracked: 165 weeks across 12 stage runs.

EWTX among Biotechnology27th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…27	EWTXEdgewise Therapeutics, Inc.	Stage 3 · wk 2	97	−2.6%

vs 52W High

-17.3%

$14.89 lo$48.35 hi

17.3% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 2

1w13w26w

Week 2, early distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

11.5%

200 DMA: $35.85 · rising

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

0.93x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-2.6%

-2.1%

+28.1%

YTD

+68.4%

+157.8%

Scan Membership

Breakout Watch

Latest: 2024-05-17

3 appearances in last 60 days. First seen: 2023-01-26.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 2 · Vol 0.93x

2026-10-21S3

Wk 1 · Vol 0.78x

2026-10-20S3

Wk 1 · Vol 1.52x

2026-10-19S3

Wk 1 · Vol 0.99x

2026-10-16S3

Wk 1 · Vol 0.91x

2026-10-15S32→3

Wk 1 · Vol 1.28x

2026-10-14S2

Wk 45 · Vol 0.97x

2026-10-13S2

Wk 45 · Vol 0.55x

2026-10-12S2

Wk 45 · Vol 1.04x

2026-10-09S2

Wk 44 · Vol 0.72x

2026-10-08S2

Wk 44 · Vol 0.93x

2026-10-07S2

Wk 44 · Vol 1.00x

Moving averages & range

50 DMA

$41.92

200 DMA

$35.85

52W High

$48.35

52W Low

$14.89

5D Low

$37.19

Resistance levels (recent highs)

20d High

$41.40

60d High

$46.94

120d High

$48.35

250d High

$48.35

Next resistance

+3.5%

to 20d High

ROE

-38.0%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 9.6

Edgewise Therapeutics: quick answers

What stage is Edgewise Therapeutics in?

As of Oct 22, 2026, Edgewise Therapeutics (EWTX) is in Stage 3, the topping phase. It entered Stage 3 on Oct 15, 2026 and is in week 2. What the four stages mean

Is Edgewise Therapeutics in an uptrend?

Its uptrend has stalled. Edgewise Therapeutics is in Stage 3, the topping phase that follows an advance. It trades 11.5% above its 200-day average, which is rising.

How far is Edgewise Therapeutics from its 52-week high?

Edgewise Therapeutics closed at $39.99 on Oct 22, 2026, 17.3% below its 52-week high of $48.35. Its 52-week low is $14.89.

How has Edgewise Therapeutics performed over the past year?

As of Oct 22, 2026, Edgewise Therapeutics is up 157.8% over the past year and up 68.4% so far in 2026.

Which sector and industry is Edgewise Therapeutics in?

Edgewise Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.